Skip to main content

Table 3 Neuromotor developmental milestones (ITTE population)

From: Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial

Characteristics

Visit

Statistics

‘sapropterin continuous’ (n = 25)

‘sapropterin extension’ (n = 26)

Area of assessment fine motor skills, n (%)

Baseline

Normal

16 (69.6)

24 (92.3)

 

Abnormal

7 (30.4)

2 (7.7)

Month 12

Normal

16 (69.6)

22 (91.7)

 

Abnormal

7 (30.4)

2 (8.3)

Month 24

Normal

16 (94.1)

16 (88.9)

 

Abnormal

1 (5.9)

2 (11.1)

EOS

Normal

11 (84.6)

14 (100.0)

 

Abnormal

2 (15.4)

0

Area of assessment gross motor skills, n (%)

Baseline

Normal

21 (91.3)

19 (73.1)

 

Abnormal

2 (8.7)

7 (26.9)

Month 12

Normal

21 (91.3)

22 (91.7)

 

Abnormal

2 (8.7)

2 (8.3)

Month 24

Normal

14 (82.4)

15 (83.3)

 

Abnormal

3 (17.6)

3 (16.7)

EOS

Normal

12 (92.3)

14 (100.0)

 

Abnormal

1 (7.7)

0

Area of assessment language, n (%)

Baseline

Normal

20 (87.0)

22 (84.6)

 

Abnormal

3 (13.0)

4 (15.4)

Month 12

Normal

18 (78.3)

21 (87.5)

 

Abnormal

5 (21.7)

3 (12.5)

Month 24

Normal

14 (82.4)

14 (77.8)

 

Abnormal

3 (17.6)

4 (22.2)

EOS

Normal

12 (92.3)

11 (78.6)

 

Abnormal

1 (7.7)

3 (21.4)

Area of assessment personal-social, n (%)

Baseline

Normal

20 (87.0)

20 (76.9)

 

Abnormal

3 (13.0)

6 (23.1)

Month 12

Normal

21 (91.3)

19 (79.2)

 

Abnormal

2 (8.7)

5 (20.8)

Month 24

Normal

16 (94.1)

14 (77.8)

 

Abnormal

1 (5.9)

4 (22.2)

EOS

Normal

13 (100.0)

14 (100.0)

 

Abnormal

0

0

  1. EOS end of extension period (month 36), ITTE intention-to-treat extension (population)